TRCT
STLN

Tower Research Capital (TRC)’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Tower Research Capital (TRC)’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.5K Buy
7,314
+1,967
+37% +$6.03K ﹤0.01% 3401
2025
Q4 		$19K Sell
5,347
-8,286
-61% -$30.7K ﹤0.01% 3134
2025
Q3 		$47.6K Buy
13,633
+5,984
+78% +$20.5K ﹤0.01% 2560
2025
Q2 		$15.7K Sell
7,649
-1,894
-20% -$4.74K ﹤0.01% 3803
2025
Q1 		$10.9K Sell
9,543
-3,997
-30% -$3.09K ﹤0.01% 3599
2024
Q4 		$4.18K Buy
13,540
+4,741
+54% +$1.23K ﹤0.01% 4500
2024
Q3 		$2.88K Sell
8,799
-1,033
-11% -$428 ﹤0.01% 4930
2024
Q2 		$4.52K Buy
9,832
+2,080
+27% +$1.77K ﹤0.01% 4772
2024
Q1 		$12.2K Sell
7,752
-4,294
-36% -$8.16K ﹤0.01% 3494
2023
Q4 		$24.6K Buy
+12,046
New +$20.9K ﹤0.01% 3531
2023
Q3 		– Sell
-3,640
Closed -$2K – 6235
2023
Q2 		$2K Sell
3,640
-11,041
-75% -$5.84K ﹤0.01% 5275
2023
Q1 		$10K Buy
14,681
+7,660
+109% +$9.77K ﹤0.01% 4410
2022
Q4 		$12K Buy
7,021
+5,345
+319% +$15K ﹤0.01% 3753
2022
Q3 		$8K Sell
1,676
-2,012
-55% -$11.8K ﹤0.01% 4813
2022
Q2 		$19K Buy
3,688
+2,873
+353% +$20.9K ﹤0.01% 3861
2022
Q1 		$6K Buy
815
+615
+308% +$4.15K ﹤0.01% 4930
2021
Q4 		$2K Sell
200
-252
-56% -$2.24K ﹤0.01% 5669
2021
Q3 		$4K Buy
+452
New +$4.49K ﹤0.01% 4999
2021
Q2 		– Sell
-49
Closed – – 5845
2021
Q1 		$0 Buy
49
+48
+4,800% +$511 ﹤0.01% 5728
2020
Q4 		$0 Buy
+1
New +$10 ﹤0.01% 5408

Other funds holding STLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KWM
Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return
CP
CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s STLN Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 37% in Q1 2026, buying an estimated $6.03K and bringing the position to 7,314 shares worth $22.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3401.

Tower Research Capital (TRC) first reported a position in STLN in Q4 2020 and has held it in 20 quarters since. The position peaked at $47.6K in Q3 2025. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • Tower Research Capital (TRC) held 7,314 shares of Starling Oncology Institute, Inc. Common Stock worth $22.5K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,967 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $6.03K.
  • Starling Oncology Institute, Inc. Common Stock made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3401 holding.
  • Tower Research Capital (TRC) first reported a position in Starling Oncology Institute, Inc. Common Stock in Q4 2020 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Starling Oncology Institute, Inc. Common Stock position peaked at $47.6K in Q3 2025.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.